Q-omics provides the consensus-scored ISG15 profile across patient tissues and cancer cell-line models. ISG15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ISG15 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ISG15 protein abundance shows 14,907 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where ISG15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISG15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISG15 survival associations across molecular data types. ISG15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISG15 RNA expression–survival associations across cancer types. High ISG15 expression shows unfavorable associations in KIRC, UVM, ACC and LGG, but favorable associations in SKCM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ISG15 RNA expression.
This table summarizes ISG15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ISG15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISG15 shows higher tumor expression in HNSC, KIRC, BLCA, STAD, THCA and BRCA. The HNSC box plot shows higher ISG15 RNA expression in tumor versus normal tissue (log2 FC = +4.858, t-test p < 0.001).
This table shows molecular features associated with ISG15 in patient tissues and cancer cell lines. In patient samples, ISG15 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ISG15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
